Comparable roles of CD44v8‑10 and CD44s in the development of bone metastases in a mouse model

Hiraga,Toru; Nakamura,Hiroaki

doi:10.3892/ol.2016.4985

Comparable roles of CD44v8‑10 and CD44s in the development of bone metastases in a mouse model

Authors:
- Toru Hiraga
- Hiroaki Nakamura
View Affiliations

Affiliations: Department of Histology and Cell Biology, Matsumoto Dental University, Nagano 399‑0781, Japan
Published online on: August 10, 2016 https://doi.org/10.3892/ol.2016.4985
Pages: 2962-2969

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cluster of differentiation (CD)44 has been implicated in cancer metastasis to bone. Clinical and experimental studies have suggested that the standard isoform of CD44 (CD44s) and the variant isoform of CD44 (CD44v) enhance metastasis. The present study examined the differential roles of CD44s and CD44v, particularly CD44v8‑10, in the development of bone metastases. For this purpose, MDA‑MB‑231 human breast cancer cells and A549 human lung cancer cells were stably transduced with epithelial splicing regulatory protein 1 (ESRP1), which regulates the alternative splicing of several genes, including CD44. The introduction of ESRP1 induced a splicing switch from CD44s to CD44v, particularly to CD44v8‑10, while the total amount of CD44 was rarely affected. However, ESRP1 did not significantly affect cell proliferation, migration, invasion or tumor sphere formation in vitro. Furthermore, ESRP1 did not cause significant differences in the development of bone metastases in a mouse model. As an alternative approach, cancer cells transduced with the CD44v8‑10 gene were also established. The overexpression of CD44v8‑10 in MCF‑7 human breast cancer cells, which rarely express any isoform of CD44, promoted cell migration and sphere formation, whereas the overexpression of CD44v8‑10 in MDA‑MB‑231 cells, which endogenously express high levels of CD44s, did not exert these effects. The results of the present study collectively suggest that the ability of CD44v8‑10 to promote tumor aggressiveness and bone metastases is similar to that of CD44s. CD44v8‑10 and CD44s may represent potential therapeutic targets for the treatment of bone metastases.

View Figures

View References

1	Ponta H, Sherman L and Herrlich PA: CD44: From adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol. 4:33–45. 2003. View Article : Google Scholar : PubMed/NCBI
2	Zöller M: CD44: Can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer. 11:254–267. 2011. View Article : Google Scholar : PubMed/NCBI
3	Visvader JE and Lindeman GJ: Cancer stem cells: Current status and evolving complexities. Cell Stem Cell. 10:717–728. 2012. View Article : Google Scholar : PubMed/NCBI
4	Günthert U, Hofmann M, Rudy W, Reber S, Zöller M, Haussmann I, Matzku S, Wenzel A, Ponta H and Herrlich P: A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell. 65:13–24. 1991. View Article : Google Scholar : PubMed/NCBI
5	Friedrichs K, Franke F, Lisboa BW, Kügler G, Gille I, Terpe HJ, Hölzel F, Maass H and Günthert U: CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer. Cancer Res. 55:5424–5433. 1995.PubMed/NCBI
6	Seelentag WK, Günthert U, Saremaslani P, Futo E, Pfaltz M, Heitz PU and Roth J: CD44standard and variant isoform expression in human epidermal skin tumors is not correlated with tumor aggressiveness but down-regulated during proliferation and tumor de-differentiation. Int J Cancer. 69:218–224. 1996. View Article : Google Scholar : PubMed/NCBI
7	Olsson E, Honeth G, Bendahl PO, Saal LH, Gruvberger-Saal S, Ringnér M, Vallon-Christersson J, Jönsson G, Holm K, Lövgren K, et al: CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers. BMC Cancer. 11:4182011. View Article : Google Scholar : PubMed/NCBI
8	Okamoto I, Morisaki T, Sasaki J, Miyake H, Matsumoto M, Suga M, Ando M and Saya H: Molecular detection of cancer cells by competitive reverse transcription-polymerase chain reaction analysis of specific CD44 variant RNAs. J Natl Cancer Inst. 90:307–315. 1998. View Article : Google Scholar : PubMed/NCBI
9	Yamaguchi A, Urano T, Goi T, Saito M, Takeuchi K, Hirose K, Nakagawara G, Shiku H and Furukawa K: Expression of a CD44 variant containing exons 8 to 10 is a useful independent factor for the prediction of prognosis in colorectal cancer patients. J Clin Oncol. 14:1122–7112. 1996.PubMed/NCBI
10	Yamaguchi A, Saito M, Goi T, Iida A, Takeuchi K, Hirose K, Nakagawara G, Urano T, Furukawa K and Shiku H: Expression of CD44 variant exons 8-10 in gastric cancer. Jpn J Cancer Res. 86:1166–1171. 1995. View Article : Google Scholar : PubMed/NCBI
11	Lau WM, Teng E, Chong HS, Lopez KA, Tay AY, Salto-Tellez M, Shabbir A, So JB and Chan SL: CD44v8-10 is a cancer-specific marker for gastric cancer stem cells. Cancer Res. 74:2630–2641. 2014. View Article : Google Scholar : PubMed/NCBI
12	Zeng Y, Wodzenski D, Gao D, Shiraishi T, Terada N, Li Y, Vander Griend DJ, Luo J, Kong C, Getzenberg RH and Kulkarni P: Stress-response protein RBM3 attenuates the stem-like properties of prostate cancer cells by interfering with CD44 variant splicing. Cancer Res. 73:4123–4133. 2013. View Article : Google Scholar : PubMed/NCBI
13	Weilbaecher KN, Guise TA and McCauley LK: Cancer to bone: A fatal attraction. Nat Rev Cancer. 11:411–425. 2011. View Article : Google Scholar : PubMed/NCBI
14	Abraham BK, Fritz P, McClellan M, Hauptvogel P, Athelogou M and Brauch H: Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res. 11:1154–1159. 2005.PubMed/NCBI
15	Balic M, Lin H, Young L, Hawes D, Giuliano A, McNamara G, Datar RH and Cote RJ: Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res. 12:5615–5621. 2006. View Article : Google Scholar : PubMed/NCBI
16	Hiraga T, Ito S and Nakamura H: Cancer stem-like cell marker CD44 promotes bone metastases by enhancing tumorigenicity, cell motility, and hyaluronan production. Cancer Res. 73:4112–4122. 2013. View Article : Google Scholar : PubMed/NCBI
17	Nakamura H, Kato R, Hirata A, Inoue M and Yamamoto T: Localization of CD44 (hyaluronan receptor) and hyaluronan in rat mandibular condyle. J Histochem Cytochem. 53:113–120. 2005. View Article : Google Scholar : PubMed/NCBI
18	Warzecha CC, Sato TK, Nabet B, Hogenesch JB and Carstens RP: ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing. Mol Cell. 33:591–601. 2009. View Article : Google Scholar : PubMed/NCBI
19	Brown RL, Reinke LM, Damerow MS, Perez D, Chodosh LA, Yang J and Cheng C: CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest. 121:1064–1074. 2011. View Article : Google Scholar : PubMed/NCBI
20	Yae T, Tsuchihashi K, Ishimoto T, Motohara T, Yoshikawa M, Yoshida GJ, Wada T, Masuko T, Mogushi K, Tanaka H, et al: Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell. Nat Commun. 3:8832012. View Article : Google Scholar : PubMed/NCBI
21	Bartolazzi A, Jackson D, Bennett K, Aruffo A, Dickinson R, Shields J, Whittle N and Stamenkovic I: Regulation of growth and dissemination of a human lymphoma by CD44 splice variants. J Cell Sci. 108:1723–1733. 1995.PubMed/NCBI
22	Oskarsson T, Batlle E and Massagué J: Metastatic stem cells: Sources, niches, and vital pathways. Cell Stem Cell. 14:306–321. 2014. View Article : Google Scholar : PubMed/NCBI